Compare BridgeBio Pharma Inc (BBIO) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs United Microelectronics Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while United Microelectronics Corp trades at $19.19 (market cap $47.80B). The key difference: United Microelectronics Corp is far larger — about 2.9× BridgeBio Pharma Inc's market cap, and United Microelectronics Corp pays a 2.13% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | UMC | |
|---|---|---|
Market Cap | $16.61B | $47.80B |
Sector | Health | Technology |
52-Week High | $90.17 | $28.02 |
52-Week Low | $47.29 | $6.58 |
Enterprise Value | $18.16B | $44.92B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
UMC trades at $18.72, down 2.5% today, amid a bearish technical signal with key resistance at $19. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.54 vs. $0.16 expected, and announced fab expansions in Singapore and Taiwan to meet AI-driven demand. Revenue growth is projected to rise to $250.7B in 2026, with a net income margin of 32.75%, though profit margins have declined from 2022 peaks. Analyst sentiment is mixed, with 26.7% buy ratings but a majority hold consensus.
The outlook for UMC is cautiously optimistic, driven by AI expansion and solid profitability, but risks include competitive pressures and margin compression. Near-term price action hinges on breaking resistance at $19, with support at $18. Institutional activity shows mixed positioning, reflecting uncertainty over execution amid capital expenditure increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
